Command Palette

Search for a command to run...

Preprint WatchMildSeptember 2nd, 2026

Dissecting the TMEM132A-EGFR Dependency to Unlock Translational Therapeutic Opportunities for Pan-Solid Tumor

Liu, X.; Fu, Y.; Ni, Q.; Ning, C.; Wang, J.; Wu, M.; Zhang, C.; Wang, J.; Qian, J.; Fang, W.; Zhang, D.; Li, X.; Zhao, F.; Gong, L.; Yao, J.; Song, N.; He, Y.; Wei, X.; Qin, C.; Wang, J.

TMEM132A binds EGFR directly, stabilises it at the plasma membrane and sustains SREBP-driven lipogenesis, and a nanobody blocking the TMEM132A-EGFR interaction retains antitumor activity in an EGFR-TKI-resistant H1975 xenograft.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

This preprint identifies TMEM132A as a direct EGFR-binding partner that tethers EGFR at the plasma membrane and sustains lipogenic signaling, and reports that a nanobody disrupting that interaction inhibits growth in an H1975 xenograft resistant to first- and second-generation EGFR inhibitors. The Claidex record for EGFR contains one documented failure, bg-60366-egfr-cdac-nsclc-strategic-shutdown, a chimeric degrader program in EGFR-mutant non-small cell lung cancer closed on a sponsor decision rather than on data. Severity here is mild because the prior failure was operational and carries no efficacy read. The preprint is nonetheless a live claim about the same target space: it proposes that EGFR localisation and stabilisation, rather than kinase activity alone, is the tractable node in resistant disease. That is a different hypothesis from degradation and from kinase inhibition, and it has been tested only in xenografts.

Abstract excerpt

Solid tumors remain refractory to conventional treatments, yet cell surface proteins, by virtue of their extracellular accessibility and critical roles in tumor signaling, represent an attractive class of targets for precision-targeted therapy. Here, we report that TMEM132A is an essential and previously unrecognized pan-cancer target. TMEM132A interacts directly with EGFR and stabilizes its expression, thereby tethering EGFR at the plasma membrane and sustaining constitutive activation of lipid synthesis. Mechanistically, the TMEM132A-EGFR axis promotes lipogenesis by facilitating SREBP nuclear translocation, which in turn upregulates ACLY and ACSS2 expression to drive acetyl-CoA production and downstream lipid biosynthesis, ultimately disrupting lipid droplet homeostasis. To therapeutically target this axis, we developed a nanobody, LFNanoT132A#3, which effectively blocks the TMEM132A-EGFR interaction, abrogates downstream signaling activation, and potently inhibits proliferation across multiple solid tumor types. Notably, LFNanoT132A also exerts robust antitumor activity against H1975 xenografts, a model resistant to first- and second- generation EGFR inhibitors, underscoring its potential to overcome conventional drug resistance. Our findings establish TMEM132A#3 as a critical node in membrane-tethered oncogenic signaling and metabolic rewiring, and position LFNanoT132A#3 as a promising therapeutic candidate for precision cancer therapy.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.